Nanobiotix (NASDAQ:NBTX) Announces Quarterly Earnings Results

Nanobiotix (NASDAQ:NBTX) released its quarterly earnings data on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.43), FiscalAI reports. The firm had revenue of $3.42 million for the quarter, compared to the consensus estimate of $41.95 million.

Nanobiotix Trading Up 0.9%

NBTX opened at $30.87 on Wednesday. The firm’s 50 day moving average is $27.62 and its 200-day moving average is $23.12. Nanobiotix has a 52-week low of $2.99 and a 52-week high of $41.89.

Institutional Investors Weigh In On Nanobiotix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its holdings in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Nanobiotix during the fourth quarter valued at about $220,000. Finally, Millennium Management LLC acquired a new stake in shares of Nanobiotix during the fourth quarter valued at about $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Analyst Ratings Changes

NBTX has been the topic of several recent research reports. Guggenheim lifted their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 6th. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Nanobiotix currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.